Today: 10 June 2026
Opendoor (OPEN) News Today — Nov 12, 2025: CEO Kaz Nejatian Buys $1M in Stock as Warrant Dividend Nears; Shares Hold Gains
12 November 2025
2 mins read

Opendoor (OPEN) News Today — Nov 12, 2025: CEO Kaz Nejatian Buys $1M in Stock as Warrant Dividend Nears; Shares Hold Gains

Opendoor Technologies Inc. (NASDAQ: OPEN) is back in the spotlight today after CEO Kaz (Kasra) Nejatian disclosed the open‑market purchase of 125,000 shares—about $1.0 million—ahead of next week’s special warrant dividend. The insider buy, recorded in a Form 4 filed this morning, adds to the stock’s momentum following Monday’s 21% surge.

What happened today

  • Insider purchase: Nejatian bought 125,000 OPEN shares on Nov. 11 at a weighted‑average price of $8.0365, bringing his direct holdings to ~83.48 million shares. The transaction and totals are detailed in the CEO’s SEC Form 4 filed Nov. 12.
  • Stock check: As of 14:26 UTC, OPEN traded around $8.48 intraday, modestly higher as investors digested the filing and looked ahead to the warrant distribution. (See live chart above.)
  • Context: The insider buy follows Monday’s outsized move (+21.5%) that came in the wake of last week’s earnings and a novel warrant dividend plan that has energized Opendoor’s retail investor base.

The warrant dividend: key facts & dates investors need to know

Opendoor’s special dividend of tradable warrants remains the near‑term catalyst. Official details from the company’s Form 8‑K and shareholder FAQ:

  • Record date:Nov. 18, 2025 (5:00 p.m. New York time).
  • Distribution date:On or about Nov. 21, 2025.
  • Ratio:1 warrant of each series (K, A, Z) for every 30 common shares held (rounded down).
  • Exercise prices:$9 (Series K), $13 (Series A), $17 (Series Z).
  • Expected tickers:OPENW (K), OPENL (A), OPENZ (Z) on Nasdaq.
  • Expiry:On or about Nov. 20, 2026, with early‑expiration triggers if the stock trades above preset thresholds for a sustained period.

Why it matters: issuing tradable warrants to existing holders can reward long‑term shareholders and, in the near term, complicate short positions that must account for the warrant entitlement—one reason cited for recent volatility.

Earnings & operating backdrop

Opendoor reported Q3 2025 revenue of ~$915 million and a GAAP net loss of ~$90 million last week. Shares initially fell after hours but quickly reversed as investors focused on the new strategy and capital actions.

Management has emphasized a refocus on software and AI‑driven operations, faster resale cycles, and improved unit economics as it works toward profitability targets.

Capital moves you should know about

Alongside the warrant plan, Opendoor entered into a registered direct equity offering on Nov. 6 (T+5 settlement expected Nov. 13). Net proceeds are being used to repurchase approximately $264 million principal amount of its 2030 convertible notes; the company does not expect a material change to cash after these cross‑conditional transactions.

Market color: positioning & sentiment

Opendoor remains a heavily shorted name—part of the bull/bear tug‑of‑war that has amplified moves. The planned warrant distribution has been framed by some as adding complexity for shorts, potentially encouraging short covering into the record date.

By the numbers (Nov 12, 2025)

  • Price (intraday): ~$8.48 (14:26 UTC)
  • Insider buy: 125,000 shares @ $8.0365; ~$1.0M total; 83.48M shares now held directly by CEO.
  • Recent move: +21.5% on Nov. 10 session.

What to watch next

  • Nov. 13: Expected settlement of the registered direct offering tied to the notes repurchase.
  • Nov. 18:Record date for the warrant dividend (holders must be on record by 5:00 p.m. ET).
  • Week of Nov. 24:Nasdaq trading for OPENW / OPENL / OPENZ can begin the first trading day after the distribution date, subject to approval.

Editorial note

This article focuses on news dated today (Nov 12, 2025)—notably the CEO’s Form 4 purchase—and the immediate catalysts affecting Opendoor shares. As always, this coverage is for informational purposes only and not investment advice.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Nuvalent Shares Rally Near $124 on GSK's $10.6 Billion Acquisition Offer
    June 10, 2026, 8:58 AM EDT. Nuvalent's stock surged nearly 40% to $123.25 after GSK announced a $10.6 billion cash acquisition at $124 per share, a 40% premium over the previous close. Investors are now pricing the biotech as a takeover target rather than a typical high-risk drug developer. GSK's tender offer is expected within 10 business days, pending U.S. antitrust clearance. The deal includes late-stage lung cancer drugs zidesamtinib and neladalkib, both FDA Breakthrough Therapy-designated kinase inhibitors, with regulatory decisions due in late 2026. GSK aims to boost revenue and profits from 2027. Nuvalent's board supports the offer. The agreement includes a $350 million breakup fee to discourage competing bids.

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
Anthropic’s Private Shares Soar to $185 Amid AI Frenzy – $183B Valuation, Major Deals & $1.5B Lawsuit
Previous Story

Anthropic Poised to Beat OpenAI to Profitability as It Diversifies Beyond Nvidia — What’s New Today (Nov. 12, 2025)

Alien Probe or Cosmic Relic? Interstellar Comet 3I/ATLAS Baffles Scientists (updated 27.10.2025)
Next Story

Comet 3I/ATLAS on Nov. 12, 2025: Tail Keeps Growing, First Radio Signal Confirmed, and How to See the Interstellar Visitor

Go toTop